[go: up one dir, main page]

MX2023006732A - Composiciones y metodos de prolongacion de la vida media. - Google Patents

Composiciones y metodos de prolongacion de la vida media.

Info

Publication number
MX2023006732A
MX2023006732A MX2023006732A MX2023006732A MX2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A
Authority
MX
Mexico
Prior art keywords
life extending
methods
antibody
compositions
extending compositions
Prior art date
Application number
MX2023006732A
Other languages
English (en)
Inventor
David Campbell
Thomas R Diraimondo
Ramesh Bhatt
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of MX2023006732A publication Critical patent/MX2023006732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Lubricants (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se describen polipéptidos y complejos de polipéptidos que comprenden un anticuerpo o fragmento de anticuerpo que prolonga la vida media. En algunas modalidades, el anticuerpo o fragmento de anticuerpo de extensión de vida media es un anticuerpo de dominio individual.
MX2023006732A 2020-12-08 2021-12-07 Composiciones y metodos de prolongacion de la vida media. MX2023006732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122818P 2020-12-08 2020-12-08
PCT/US2021/062238 WO2022125566A1 (en) 2020-12-08 2021-12-07 Half-life extending compositions and methods

Publications (1)

Publication Number Publication Date
MX2023006732A true MX2023006732A (es) 2023-08-14

Family

ID=81973740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006732A MX2023006732A (es) 2020-12-08 2021-12-07 Composiciones y metodos de prolongacion de la vida media.

Country Status (9)

Country Link
US (1) US20240034814A1 (es)
EP (1) EP4259178A4 (es)
JP (1) JP2023552462A (es)
KR (1) KR20230156897A (es)
CN (1) CN117042788A (es)
AU (1) AU2021397734A1 (es)
CA (1) CA3201560A1 (es)
MX (1) MX2023006732A (es)
WO (1) WO2022125566A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
TW202237654A (zh) 2020-12-09 2022-10-01 美商詹努克斯治療有限公司 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
EP1558650A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
US9175071B2 (en) * 2009-02-19 2015-11-03 Glaxo Group Limited Anti-serum albumin binding variants
SG11202004144VA (en) * 2017-11-17 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-l1
WO2019204925A1 (en) * 2018-04-24 2019-10-31 National Research Council Of Canada Serum albumin binding antibodies for tuneable half-life extension of biologics
JP2022520998A (ja) * 2019-02-22 2022-04-04 アンウィタ バイオサイエンシス， インク． アルブミン結合抗体及びその使用

Also Published As

Publication number Publication date
EP4259178A1 (en) 2023-10-18
AU2021397734A1 (en) 2023-07-06
WO2022125566A1 (en) 2022-06-16
AU2021397734A9 (en) 2024-09-05
JP2023552462A (ja) 2023-12-15
KR20230156897A (ko) 2023-11-15
CN117042788A (zh) 2023-11-10
CA3201560A1 (en) 2022-06-16
US20240034814A1 (en) 2024-02-01
EP4259178A4 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
SA521422394B1 (ar) Ccr8 جسم مضاد جديد لـ
MX2024008677A (es) Conjugados de camptotecina.
MX2023006732A (es) Composiciones y metodos de prolongacion de la vida media.
EP4464721A3 (en) Heterotandem bicyclic peptide complexes
WO2020160156A3 (en) Anti-gal3 antibodies and uses thereof
CR20190593A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
MX2020008030A (es) Anticuerpos de glipicano 3 y conjugados de los mismos.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
HRP20050354B1 (es)
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
TW200738750A (en) Ligands and methods of use therefor
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
TW200732349A (en) Anti-OX40L antibodies and methods using same
GEP20105118B (en) Anti-vegf antibodies
MX2022014653A (es) Composiciones de antigeno de coronavirus y sus usos.
MX2023011561A (es) Anticuerpos anti-nectina-4 y usos de los mismos.
WO2022082073A3 (en) Compositions and methods for muc18 targeting
PH12022550246A1 (en) A dosing regimen for an ido inhibitor
ZA202309516B (en) Anti-ccr8 antibodies
NZ776865A (en) Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
MX2022011077A (es) Variantes de transglutaminasa.
WO2021011944A3 (en) Imaging based homogeneous assay
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
ATE469177T1 (de) Bauadditive auf basis von gereinigtem hydrophobisch modifiziertem hydroxyalkyl guar